Similar to the basal tissue samples, a highly significant association between HER2-low-positive expression on residual disease and HR status was observed (HER2-low-positive proportion among HR-positive and triple-negative cases: 65.4% vs. 37.6%, respectively, p < 0.001 χ 2 test).
← all excerpts
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment.
1
—
—